Posted by Michael Wonder on 21 Feb 2022
Proposed PMPRB regulations requires focused dialogue with all players
16 February 2022 - Canada needs an approach that balances pricing considerations with the need to encourage investment, foster innovation, and most of all, ensures Canadians have timely access to the most innovative, life saving new medicines.
In December Health Minister Jean-Yves Duclos formally announced the government was delaying the implementation of the Patented Medicine Prices Review Board regulatory changes by six months.
